PRO Therapeutics

What PRO Therapeutics does

PRO Therapeutics, LLC is an early-stage regenerative medicine company headquartered in Manchester, New Hampshire, developing tissue-engineered biologic grafts for soft tissue repair in tendons, ligaments, and muscles. Its core product is a non-cellular rotator cuff graft designed to catalyze the body's own biological healing process by providing an underlayment that enables migration of cells from bone, thereby enhancing regeneration of the tendon-to-bone interface and reducing post-surgical re-tear rates that currently range from 26% to 94% depending on severity and patient age. The technology originates from University of Michigan research by co-founders Lisa Larkin, PhD and Ellen M. Arruda and is being advanced in partnership with the Advanced Regenerative Manufacturing Institute (ARMI), where the company is an inaugural member of the BioFab Startup Lab co-located within ARMI's biofab foundries.

The company's commercial product strategy targets the roughly 400,000+ annual U.S. rotator cuff surgeries that cost the healthcare system more than $523 million per year, with a planned off-the-shelf, biologic graft medical device distributed through enterprise field sales to orthopedic surgeons, sports medicine physicians, and hospital systems. The platform is intended to extend beyond rotator cuff to ACL and other ligament and tendon reconstruction procedures. To date, PRO Therapeutics has not generated product revenue; its activities are funded primarily by non-dilutive government grants exceeding $5 million, including a $1.8 million NIH Direct-to-Phase-2 SBIR grant awarded in July 2023. The company is pre-clinical and preparing an Investigational New Drug (IND) application for FDA-regulated clinical trials, with leadership comprising CEO Julie Lenzer, President and CSO Lisa Larkin, PhD, and COO Adam Jakus, PhD (appointed January 2025).

Name

PRO Therapeutics

Legal name

PRO Therapeutics, LLC

Website

https://pro-thera.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

PRO Therapeutics is an early-stage, pre-clinical regenerative medicine company developing non-cellular, tissue-engineered biologic grafts to regenerate tendons, ligaments, and muscles, with its lead rotator cuff graft preparing for FDA clinical trials targeting orthopedic surgeons and hospitals.

Ownership category

akta.pro rank

Product category

Regenerative Medicine / Tissue-Engineered Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Sports Medicine & Soft Tissue Repair Implants (Anchors/Grafts/Meniscal Repair) (HLAHAEAF)

akta.pro secondary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Regenerative medicine
• Tissue-engineered grafts
• Soft tissue repair
• Orthopedic biologics
• Rotator cuff repair

Headquarters

HQ city

New Hampshire

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device/ Tissue Graft Sales: PRO Therapeutics plans to commercialize their tissue-engineered graft as an off-the-shelf product for soft tissue repair procedures. The company is currently in pre-clinical development stage with plans to enter clinical trials. Revenue will be generated through the sale of medical devices to healthcare providers and hospitals for rotator cuff and other soft tissue repair procedures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

PRO Therapeutics is developing a tissue-engineered rotator cuff graft — a non-cellular, biologic graft designed to catalyze the regeneration of soft tissue to bone. The graft encourages the body's own biological healing process and provides an underlayment that allows migration of cells from bone to enhance the regenerative capacity of the tendon to bone. The product is being prepared for sale as an off-the-shelf medical device to hospitals and surgeons for rotator cuff repair and other soft tissue reconstruction procedures.

Product overview

PRO Therapeutics is developing a single platform product—a tissue-engineered rotator cuff graft for soft tissue repair. The graft is a non-cellular, biologic graft that serves as an underlayment allowing migration of cells from bone to enhance the regenerative capacity of the tendon to bone. The company is pursuing products for ligament and tendon injuries including rotator cuff and ACL repairs. The platform technology is designed to stimulate the body's healing potential to regenerate tendon, ligament, and muscle, with the rotator cuff graft being the primary product advancing toward clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• PRO Therapeutics Rotator Cuff Graft A tissue-engineered graft designed to catalyze the regeneration of soft tissue to bone, encouraging the body's own biological healing process and restoring normal biomechanics when used to repair tendon tears (such as rotator cuff injuries). It is a non-cellular, biologic graft that serves as an underlayment allowing migration of cells from bone to enhance the regenerative capacity of the tendon to bone. The product is being developed as an off-the-shelf medical device for orthopedic surgeons and hospitals performing soft tissue repair procedures.

Quantifiable outcome

• Regeneration of native-like tissue between bone and tendon in large animal studies
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Advanced Regenerative Manufacturing Institute (ARMI) / BioFabUSAcoreStrategic or Co-development PartnerPRO Therapeutics is a member of BioFabUSA, a program of ARMI, and has co-located its lab with ARMI's biofab foundries in the Manchester Millyard. As an inaugural member of ARMI's BioFab Startup Lab, the company works closely with ARMI's scientists and engineers to optimize product fabrication in preparation for FDA IND application and clinical trials. ARMI provides resources including access to talent, labs, regulatory support, and infrastructure to de-risk and accelerate the company's path to market.

Scale indicators6 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Stryker: Stryker is a large orthopedic and medical device incumbent with a sports medicine portfolio (e.g., through Wright Medical acquisitions) covering rotator cuff anchors, grafts, and related soft tissue repair products that overlap with PRO Therapeutics' target indication.
• Arthrex: Arthrex is the dominant player in orthopedic sports medicine and soft tissue repair, selling allograft, autograft, and synthetic graft solutions (e.g., FiberStitch, ArthroFlex) for rotator cuff, ACL, and ligament repair directly to the same orthopedic surgeon call point PRO Therapeutics intends to target.
• Integra LifeSciences: Integra LifeSciences is a regenerative tissue technologies company selling dermal, tendon, and other allograft products for orthopedic and wound care applications, with a comparable regenerative biologics business model and similar sports medicine/orthopedic call points.
• Smith+Nephew: Smith+Nephew operates a Sports Medicine & ENT franchise that includes REGENETEN bioinductive collagen implants for rotator cuff repair and other orthobiologic solutions, directly competing for the same rotator cuff and soft tissue repair indication PRO Therapeutics is pursuing.

Emerging players

• Organogenesis: Organogenesis commercializes regenerative biologic products including wound healing and soft tissue grafts from similar tissue-engineering platforms, with comparable regulatory pathway and biologic graft commercialization challenges.
• Collagen Solutions: Collagen Solutions (now part of Rosen's diversified portfolio) develops collagen-based biomaterials for tissue engineering and regenerative medicine, a comparable niche biologic material supplier serving orthopedic soft tissue repair applications.

Direct peers

• Bioventus: Bioventus is an orthobiologics company selling sports medicine products including bone graft substitutes and tendon/ligament repair solutions, directly competing in the soft tissue repair biologics market.
• MiMedx: MiMedx develops and commercializes placental tissue allografts for wound care and surgical applications including orthopedic soft tissue repair, competing in the regenerative biologic graft space with similar non-cellular tissue products.
• Vericel: Vericel develops and commercializes regenerative medicine products for orthopedic and sports medicine applications (e.g., MACI cartilage repair), operating with a similar biologic graft-based business model in the regenerative orthopedics space.
• Anika Therapeutics: Anika develops and commercializes orthobiologics including hyaluronic acid-based joint therapies and regenerative soft tissue repair products, making it a direct competitor in non-cellular biologic grafts for orthopedic indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pro-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PRO Therapeutics